Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof

A chronic heart failure and blood type technology, applied in the direction of medical formula, cardiovascular system diseases, drug combination, etc., can solve the problems that it is difficult to achieve satisfactory clinical curative effect, and can not achieve therapeutic effect, so as to reduce the dosage, enrich the existing technology, The effect of reducing adverse reactions

Active Publication Date: 2012-03-21
南通金羽禽业发展有限公司
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

From the 1940s to the 1960s, heart failure was mainly treated with the cardiorenal model, and the commonly used drugs were digitalis and diuretics; from the 1970s to the 1980s, it was switched to the cardiocirculatory model, and the main treatment was to use vasodilation on the basis of strengthening the heart and diuresis. Drugs to reduce the preload and afterload of the heart, improve hemodynamics, and try catecholamines and non-catecholamines, and Beiyang Dihuang cardiotonic drugs at the same time; since the 1990s, with the development of evidence-based medicine, the latest model of heart failure treatment has emerged. That is, the neuroendocrine comprehensive regulation mode, and the representative drugs used include: angiotensin converting enzyme inhibitor (ACEI), β receptor blocker, angiotensin receptor antagonist, etc., but none of them can achieve satisfactory therapeutic effect
[0004] All in all, in the treatment of chronic heart failure, the existing drug and non-drug therapies are difficult to achieve satisfactory clinical efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof
  • Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof
  • Western medicinal compound for preventing or treating myocardial ischemic chronic heart failure and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Effect of Ivabradine / Clopidogrel Compound on Myocardial Ischemia Chronic Heart Failure Rats

[0027] 1. Preparation and administration of chronic myocardial ischemia heart failure model

[0028] 90 male SD rats, weighing 200-250g. The animals were randomly divided into 6 groups: sham operation group (15 animals); model group (15 animals), which caused heart failure by ligation of the left coronary artery; ivabradine group (15 animals), who were given ivabradine after ligation of the left coronary artery. Clopidogrel group (15 rats) received clopidogrel therapy after ligation of the left coronary artery; Compound I group (15 rats) gave a certain dose of clopidogrel and ivabradine therapy after ligation of the left coronary artery; Compound II group (15 rats) received a certain dose of clopidogrel and ivabradine after ligation of the left coronary artery. Animal models of heart failure were established by ligating the left coronary artery between the left atri...

Embodiment 2

[0049] Example 2 Preparation of ivabradine / clopidogrel compound tablet

[0050] Prescription composition:

[0051]

[0052] Preparation Process:

[0053] Weigh ivabradine and clopidogrel hydrogen sulfate according to the prescription quantity, use mannitol and microcrystalline cellulose as fillers, low-substituted hydroxypropyl cellulose as disintegrant, 15% starch slurry as binder, stearin Magnesium acid is used as a lubricant, and it is granulated in one step in a fluidized bed, and then compressed into tablets.

Embodiment 3

[0054] Example 3 Preparation of ivabradine / clopidogrel compound tablet

[0055] Prescription composition:

[0056]

[0057]

[0058] Preparation Process:

[0059] Weigh ivabradine and clopidogrel hydrogen sulfate according to the prescription, use microcrystalline cellulose and starch as fillers, cross-linked sodium carboxymethyl cellulose and cross-linked povidone as disintegrants, 5% PVP 60 The % ethanol solution is used as a binder, magnesium stearate is used as a lubricant, and it is granulated in a fluidized bed in one step, and then compressed into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for preventing or treating patients with myocardial ischemic chronic heart failure and an application thereof. Active components of the composition are composed of ivabradine and clopidogrel or its pharmaceutically acceptable salts, wherein the pharmaceutically acceptable salts are bisulfate, sulfate, camphorsulfonate and hydrochloride. The western medicinal compound provided by the invention can be used to cooperatively treat patients with myocardial ischemic chronic heart failure and simultaneously reduce adverse effects of the medicine.

Description

technical field [0001] The invention relates to a western medicine compound, in particular to a western medicine compound for preventing or treating myocardial ischemia type chronic heart failure and its use, and belongs to the technical field of western medicine compound. Background technique [0002] Chronic heart failure refers to chronic primary cardiomyopathy and long-term pressure or volume overload of the ventricle, which weakens myocardial contractility and cannot maintain cardiac output. Divided into left-sided, right-sided heart failure and total heart failure. Common causes are rheumatic heart disease, hypertension, ischemic heart disease, myocarditis, aortic stenosis or regurgitation, ventricular septal defect, pulmonary heart disease, pulmonary stenosis, etc. The clinical manifestations of left heart failure: (1) dyspnea: it is the earliest and most common symptom of left heart failure. Mainly include exertional dyspnea, orthopnea and nocturnal paroxysmal dysp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/55A61K31/4365A61P9/04
Inventor 不公告发明人
Owner 南通金羽禽业发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com